Status:
COMPLETED
Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
Lead Sponsor:
Stallergenes Greer
Conditions:
Allergy
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis
Eligibility Criteria
Inclusion
- Male or female outpatients aged 18 to 50 years
- Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons
- Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens
- A score of greater than or equal to 12 out of a possible 18 on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS)
Exclusion
- Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to sensitisation to allergens other than grass pollen must not be included. Patients must be asymptomatic to all other allergens during the grass pollen season. Patients who have allergic rhinitis due to perennial allergen may not be included.
- Asthma requiring treatment other than beta-2 inhaled agonists.
- Patients who have received any desensitisation treatment for grass pollen or with any other allergen within the previous 5 years.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
633 Patients enrolled
Trial Details
Trial ID
NCT00418379
Start Date
December 1 2006
End Date
September 1 2011
Last Update
May 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DIDIER
Toulouse, France, 31400